UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

~~Date~~DATE OF ofREPORT ~~report~~ (~~Date~~DATE ofOF ~~earliest~~EARLIEST ~~event~~EVENT ~~reported~~REPORTED): May 2, 2018

~~January 30~~Hoverink Biotechnologies, ~~2018~~Inc.

Hoverink Biotechnologies Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	~~000-54830~~	46000-~~3590875~~55055	82-3445013
(State or Other Jurisdiction of Incorporation)	~~(Commission File Number)~~	(~~IRS~~Commission ~~Employer~~File ~~Identification No.~~Number)	(IRS Employer Identification No.)
	1801 Century Park East, 24 Floor Los Angeles, California 90067

1801 Century Park East, 24^th floor

Los Angeles, California 90067

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code:

866-443-4666

Former name or former address, if changed since last report:

HOVERINK INTERNATIONAL HOLDINGS, INC.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Written~~Indicate by ~~communications~~check ~~pursuant~~mark towhether the registrant is an emerging growth company as defined in Rule ~~425~~405 ~~under~~of the Securities Act ~~(17~~of ~~CFR~~1933 (§230.~~425~~405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨Emerging growth company [ ]

~~Soliciting~~If an ~~material~~emerging ~~pursuant~~growth tocompany, ~~Rule~~indicate ~~14a-12~~by ~~under~~check mark if the ~~Exchange~~registrant ~~Act~~has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(17a) ~~CFR~~of ~~240~~the Exchange Act.~~14a-12)~~ [ ]

¨Item 8.01 Other Events.

~~Pre-commencement~~On April ~~communications~~27, ~~pursuant~~2018 Hoverink Biotechnologies, Inc announced it intends to ~~Rule~~offer, ~~14d-~~subject to market and other conditions, $2~~(b)~~.5 ~~under~~million of Series A Convertible Notes offering to qualified buyers. A press release relating to the ~~Exchange~~notes ~~Act~~is ~~(17~~attached ~~CFR~~hereto ~~240~~as Exhibit 99.~~14d-2(b))~~1.

¨Section 9 - FINANCIAL STATEMENTS AND EXHIBITS

~~Pre-commencement~~Item ~~communications~~9.01 ~~pursuant~~Financial toStatements ~~Rule~~and ~~13e-4(c) under the Exchange Act (17 CFR 240~~Exhibits.~~13e-4(c))~~

~~Item 4.02~~(ad) ~~Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.~~ Exhibits

On Jan 28, 2018, the Board of Directors (the “Board”) of Hoverink Biotechnologies, Inc. (the “Company”), determined that the following financial statements previously filed by the Company with the Securities and Exchange Commission (the “SEC”) should no longer be relied upon: (1) the unaudited consolidated financial statements as of and for the years ended December 31, 2016, 2015 and the filing did not contain the independent registered public accounting firm’s reports and (2) the unaudited condensed consolidated financial statements as of and for each of the interim periods within the years ended December 31, 2015, 2016 and 2017 and for the interim periods ended March 31, June 30 and September 30, 2017. Similarly, related press releases, earnings releases, management’s report on the effectiveness of internal control over financial reporting as of December 31, 2015, 2016 and 2017 and investor communications describing the Company’s financial statements for these periods should no longer be relied upon.

Exhibit Number		Description

99.1		Press Release Hoverink Biotechnologies, Inc announced today it intends to offer $2.5 million of Series A Convertible Notes, to qualified buyers.

The Company has determined that the financial statements referred to above should be restated in order to give effect primarily to include the independent registered public accounting firm’s reports. The Company is continuing its review and quantification of these and potentially other less significant matters, which are expected to be reflected in the restated financial statements. The Company intends to file with the SEC, as soon as practicable, restated financial information for the affected periods.

The Company expects that its Annual Report on Form 10-K for the year ended December 31, 2017 will be filed by March 30, 2018.

The Company’s management and the Audit Committee have discussed the matters disclosed under this Item 4.02 with the Company’s current independent registered public accounting firm, Berkower, LLC.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “may increase,” “forecast” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts. Forward-looking statements are based on management’s current expectations or beliefs about the Company’s future plans, expectations and objectives, including, but not limited to, certain expected financial results and estimates. These forward- looking statements are not historical facts and are subject to risks and uncertainties that could cause the actual results to differ materially from those projected in these forward-looking statements including, but not limited to, the timing and nature of the final resolution of the accounting issues discussed in this Current Report on Form 8-K; any delay in the filing of required periodic reports with the SEC; the timing and results of the review of the effectiveness of internal control over financial reporting (and related internal controls) and disclosure controls and procedures; whether the review is expanded to additional matters; changes in the adjustments in this Current Report on Form 8-K due to the audit of our annual financial statements; the SAS 100 review of quarterly financial statements; our responses to potential comments from the staff of the SEC; whether a restatement of financial results will be required for other accounting issues for the same or other periods in addition to the restatement currently expected by management; additional uncertainties related to accounting issues generally; adverse effects on our business as a result of the restatement process or the review of the effectiveness of internal control over financial reporting and disclosure controls and procedures or the reactions to such event by our business partners or investors, or increased regulatory, media, or financial reporting issues; any adverse developments in existing legal proceedings or the initiation of new legal proceedings; and volatility of the price of our securities. Readers of this Current Report on Form 8-K are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date of this Current Report on Form 8-K. In addition, please refer to the risk factors contained in our other filings with the SEC. The Company undertakes no obligation to publicly update or revise the forward-looking statements contained herein to reflect changed events or circumstances after the date of this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HOVERINK BIOTECHNOLOGIES INC.

	HOVERINK BIOTECHNOLOGIES, INC.

	/s/ Debbie Mae Carter
Date: May 2, 2018	Debbie Mae Carter
	Chief Executive Officer

Date: Jan 30, 2018

Debbie Mae Carter Chief Executive Officer

Filing Compare · Hoverink Biotechnologies, Inc.